State Street Corp Buys 18,592 Shares of Pulmonx Co. (NASDAQ:LUNG)

State Street Corp boosted its position in shares of Pulmonx Co. (NASDAQ:LUNG) by 2.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 747,028 shares of the company’s stock after purchasing an additional 18,592 shares during the quarter. State Street Corp owned about 1.89% of Pulmonx worth $6,193,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of LUNG. FMR LLC increased its position in Pulmonx by 11.2% during the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock valued at $48,686,000 after purchasing an additional 591,859 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Pulmonx by 5.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock worth $9,238,000 after buying an additional 55,279 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in Pulmonx by 1.0% during the second quarter. Victory Capital Management Inc. now owns 834,301 shares of the company’s stock worth $5,289,000 after buying an additional 8,004 shares during the period. PFM Health Sciences LP bought a new position in shares of Pulmonx in the 3rd quarter worth $3,058,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Pulmonx by 5.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 313,169 shares of the company’s stock worth $2,596,000 after purchasing an additional 15,543 shares during the last quarter. 91.04% of the stock is owned by institutional investors.

Insider Activity

In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $6.63, for a total transaction of $132,600.00. Following the sale, the director now owns 1,071,974 shares of the company’s stock, valued at $7,107,187.62. The trade was a 1.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Geoffrey Beran Rose sold 4,376 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $6.18, for a total transaction of $27,043.68. Following the sale, the insider now directly owns 291,057 shares of the company’s stock, valued at approximately $1,798,732.26. This represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 49,873 shares of company stock worth $324,070 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on LUNG shares. Citigroup reiterated a “neutral” rating and issued a $7.50 target price (down previously from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Wells Fargo & Company reduced their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus lowered their target price on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Pulmonx presently has a consensus rating of “Moderate Buy” and an average price target of $12.75.

Pulmonx Trading Down 2.6 %

Shares of NASDAQ:LUNG opened at $6.70 on Friday. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. Pulmonx Co. has a 52-week low of $5.46 and a 52-week high of $14.84. The business has a 50-day moving average price of $6.48 and a 200-day moving average price of $6.83. The stock has a market cap of $264.57 million, a price-to-earnings ratio of -4.56 and a beta of 0.69.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same period in the previous year, the company posted ($0.39) earnings per share. Equities analysts predict that Pulmonx Co. will post -1.53 EPS for the current year.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.